Cibinqo

Generic Name: Abrocitinib
Dosage Form: tablets, for oral use

Medically reviewed by A Ras MD.  Last updated March 25, 2022

What is the Cibinqo?

Cibinqo can be prescribed that acts as a Janus Kinase (JAK) inhibitor. Cibinqo is prescribed for adults suffering from moderate to severe Atopic skin eczema (eczema) that does not respond to treatments and cannot be managed with prescription treatments which include biologic medicines, or in adults who can’t take these treatments.

Abrocitinib is a white to pale colored powder with the following chemical name: N-((1s,3s)-3-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)cyclobutyl)propane-1-sulfonamide

The solubility of abrocitinib in water is 0.04 mg/mL at 25ºC.

Abrocitinib has a molecular weight of 323.42 g/mol and a molecular formula of C14H21N5O2S. The structural formula of abrocitinib is:

Cibinqo

Each film-coated tablet contains 50 mg or 100 mg or 200 mg of abrocitinib and the following inactive ingredients: dibasic calcium phosphate anhydrous, hypromellose, iron oxide red, lactose monohydrate, Macrogol, magnesium stearate, microcrystalline cellulose, sodium starch glycolate, titanium dioxide, and triacetin.

It isn’t known whether Cibinqo is safe and effective for children.

In the initial 3 months of your treatment use Cibinqo. Do not combine Cibinqo alongside other medications that stop blood clots. Aspirin can be taken in low doses up to 81 mg daily during this time if recommended by your physician.

Mechanism of Action

It is a Janus kinase (JAK) inhibitor.

By inhibiting the adenosine triphosphate (ATP) binding site, abrocitinib inhibits JAK1 in a reversible manner. Abrocitinib was found to be more selective for JAK1 than JAK2 (28-fold), JAK3 (>340-fold), and tyrosine kinase (TYK) 2 (43-fold) in a cell-free isolated enzyme test. The impact of inhibiting individual JAK enzymes on treatment efficacy is unknown at this time. In vitro, the parent drug and active metabolites both inhibit JAK1 activity with equal selectivity.

Indication and usage

This is a Janus kinase (JAK) inhibitor for the treatment of individuals with refractory, moderate-to-severe atopic dermatitis whose illness is not effectively managed with other systemic medication products, including biologics, or when their use is not recommended.

Use of this medication in combination with other JAK inhibitors, biologic immunomodulators, or other immunosuppressants is not indicated.

Dosage and administration

  • The recommended dose is 100 milligrams taken once a day orally.
  • Patients who do not respond to 100 mg once daily should be given 200 mg orally once daily.
  • Patients with moderate renal impairment should take 50 mg once daily, or 100 mg once daily if they do not react to 50 mg once daily.
  • Patients who are poor metabolizers of CYP2C19 should take 50 mg once a day or 100 mg once daily if they are not responding to 50 mg once daily.

Detailed Cibinqo dosage information

Which is the primary information regarding Cibinqo?

This medication could result in serious side effects, such as:

Infections that are serious

This is a medication which affects the immune system. Cibinqo could reduce the capability of the immune system to fight off infections. Certain people have experienced serious infections after taking Cibinqo or similar medications such as tuberculosis (TB) as well as infections caused by fungi, bacteria or viruses which can be spread throughout the body. Certain people have died as a result of these illnesses.

You shouldn’t begin using Cibinqo if there is any type of infection unless your doctor confirms that it is safe.

There is an increased risk of getting shingles (herpes Zoster).

Following the start of Cibinqo contact your healthcare professional immediately If you experience any signs of infection. This medication may increase your risk to contract infections or make illnesses you are suffering from worse.

A higher risk of death

A higher risk of dying for people who are aged 50 and over who have at least one heart condition (cardiovascular) risk element and who are taking a medication in the class of drugs known as Janus kinase (JAK) inhibitors. Cibinqo is an inhibitor of JAK.

  1. The immune system is a major cause of cancer and

This medication could increase your chances of getting certain cancers by altering the way your immune system functions.

Inform your doctor that you’ve had any kind of cancer.

Risk of cardiovascular events

Greater risk of major cardiovascular events like stroke, heart attack, or death for people who are 50 and older with at least one cardiovascular disease (cardiovascular) risk factor and are taking medication within the class of medications known as JAK inhibitors. This is especially true in the case of smoking or having been a smoker for a while.

Some individuals taking Cibinqo have had significant cardiovascular issues.

Contact emergency medical assistance immediately If you experience any signs of heart attack or stroke after treatment with Cibinqo. These include:

Blood clots

The formation of blood clots in the veins in the leg (deep vein thrombosis, also known as DVT) or in your lungs (pulmonary embolism PE) may occur in certain people who take this medication. It could be life-threatening. Blood clots that form in blood vessels in the leg (deep vein thrombosis, also known as DVT) as well as in the lungs (pulmonary embolism PE) are more frequent for those who are 50 years old or older and have at least one coronary disease (cardiovascular) the risk factors include one of the classes of medications known as Janus kinase (JAK) inhibitors.

Variations in certain laboratory test results

Your doctor should conduct blood tests prior to you beginning taking this medication  and throughout the treatment using this medication to determine the following:

It is not recommended to consume Cibinqo in the event that your lymphocyte count or neutrophil counts, the number of red blood cells as well as platelet counts, are low. Your doctor may decide to suspend you from taking Cibinqo therapy for a short period of time in the event of changes in the results of these blood tests. You could also experience changes in other tests, for instance, the cholesterol levels in your blood.

Your healthcare professional should perform blood tests around 4 weeks after starting taking Cibinqo and four weeks following any increase in the dosage of Cibinqo to determine the blood cell count and the frequency required for other tests at the lab.

Before you take Cibinqo

Inform your doctor about any medications you take that you are taking, including prescription and non-prescription supplements such as vitamins, herbal supplements. Cibinqo and other medications may cause side consequences.

Inform your healthcare provider whether you are taking aspirin or any other antiplatelet therapy. Check out “Do not take this medication when you.” Consult your physician in case you’re unsure.

Take note of the medicines you take. Keep a list to show your doctor and pharmacist each time you receive any new medication.

How should I take the drug?

What could be the possible side effects of Cibinqo?

The most frequent adverse effects of Cibinqo are:

Read “What do you think is the most significant thing I should be aware of about Cibinqo.

Cibinqo could cause fertility issues in females. This could limit your ability to become pregnant. Discuss with your physician should you have any concerns regarding fertility.

The tear or separation of the inner lining of the back of the eyes (retinal detachment) is a common occurrence in patients suffering from atopic dermatitis and which is treated by the Cibinqo. Consult your healthcare professional right now if you notice abrupt changes in your vision after treatments with Cibinqo.

These are not the only possible side effects associated with Cibinqo.

How do I store Cibinqo?

Be sure to keep Cibinqo and all other medicines away from the reach of children.

General information on the safety of Cibinqo.

Some medicines are prescribed for reasons that are not the ones listed in the Medication Guide. Don’t use Cibinqo to treat a condition for that it is not recommended. Do not give Cibinqo to other people, even though they suffer from the same symptoms that you do. It could cause harm to them.

Label

PRINCIPAL DISPLAY PANEL – 50 MG TABLET BOTTLE LABEL

  • ALWAYS DISPENSE WITH
    MEDICATION GUIDE
  • Pfizer
    NDC 0069-0235-30
  • CIBINQO
    (abrocitinib) tablets
  • 50 mg
  • Do not crush, split, or chew the tablets.
  • 30 Tablets
    Rx only
Cibinqo

PRINCIPAL DISPLAY PANEL – 100 MG TABLET BOTTLE LABEL

  • ALWAYS DISPENSE WITH
    MEDICATION GUIDE
  • Pfizer
    NDC 0069-0335-30
  • CIBINQO
    (abrocitinib) tablets
  • 100 mg
  • Do not crush, split, or chew the tablets.
  • 30 Tablets
    Rx only

 

Cibinqo

 

PRINCIPAL DISPLAY PANEL – 200 MG TABLET BOTTLE LABEL

  • ALWAYS DISPENSE WITH
    MEDICATION GUIDE
  • Pfizer
    NDC 0069-0435-30
  • CIBINQO
    (abrocitinib) tablets
  • 200 mg
  • Do not crush, split, or chew the tablets.
  • 30 Tablets
    Rx only

 

Cibinqo

Leave a Reply